Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Multiple Myeloma × IPH-2101 × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1 Multiple Myeloma 1

Interventions

Dexamethasone 306 Bortezomib 165 Lenalidomide 160 Cyclophosphamide 151 Melphalan 112 Calcium Dobesilate 94 daratumumab 85 pomalidomide 61 carfilzomib 60 fludarabine phosphate 58 Peripheral Blood Stem Cell Transplantation 57 Filgrastim 50 Thalidomide 48 Mycophenolic Acid 45 Busulfan 45 ixazomib 43 Tacrolimus 38 Granulocyte Colony-Stimulating Factor 38 fludarabine 37 Whole-Body Irradiation 37 dexamethasone acetate 29 Etoposide 29 Cyclosporine 29 Antilymphocyte Serum 28 isatuximab 25 dexamethasone 21-phosphate 24 auricularum 23 Prednisone 22 plerixafor 21 Radiotherapy 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00999830 2016-03-24

REMYKIR

Innate Pharma

Phase 2 Completed

27 enrolled 10 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡